golvatinib
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00869895)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
KDR inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1- Mol. weight
- 633.7 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3039525 ↗
Also known as
- e7050
- e7050
- e7050
- e 7050
- e-7050
- e-7050
- e-7050
- e7050 cpd
- golvatinib
- golvatinib
- golvatinib
- golvatinib
- n-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01355302 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2011 | Eisai, IQVIA |
| NCT01433991 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2011 | Eisai |
| NCT01428141 | Phase 1 | Sep 1, 2011 | Eisai |
| NCT01332266 | Phase 1/Phase 2 (Phase 2) | May 1, 2011 | Eisai, IQVIA, PharmaBio Development Inc. |
| NCT02533102 | Phase 1 | Nov 1, 2010 | Eisai |
| NCT00921869 | Phase 1 | Oct 1, 2009 | Eisai |
| NCT00869895 | Phase 1 | Mar 1, 2009 | Eisai |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 7 | 7 | 2 | 2009 |
| IQVIA | For profit | 2 | 0 | 1 | 2011 |
| PharmaBio Development Inc. | For profit | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1